Last updated: February 20, 2026
VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a broad-spectrum fluoroquinolone antibiotic used primarily to treat bacterial conjunctivitis. It is marketed under the trade name VIGAMOX by Alcon, a Novartis division. Multiple suppliers participate in its production, distribution, and tiered supply chain.
Manufacturing and Primary Suppliers
Alcon (Novartis)
Alcon is the sole manufacturer of VIGAMOX, ensuring tight control over formulation, quality, and supply. It produces the drug at multiple facilities globally, primarily focusing on the United States, Switzerland, and other key markets.
Contract Manufacturing Organizations (CMOs)
Alcon contracts certain production processes to third-party CMOs for excipients, packaging, and logistics. While specific contract manufacturers are proprietary, typical collaboration involves:
- API production: No external API suppliers publicly disclosed due to strategic and regulatory reasons.
- Packaging: Specialized packaging facilities conforming to pharmaceutical standards.
Raw Material Suppliers
The active pharmaceutical ingredient (API), moxifloxacin hydrochloride, is supplied by several global chemical companies with manufacturing capacities compliant with Good Manufacturing Practice (GMP). Notable players include:
| Supplier |
Location |
Certification |
Estimated Market Share (API supply) |
| Zhenhua Pharmaceutical |
China |
GMP |
Large-scale API producer |
| North China Pharmaceutical |
China |
GMP |
Major API supplier |
Note: Actual market shares are proprietary; these are indicative based on trade disclosures and industry reports.
Distribution and Logistics
Distributors
VIGAMOX is distributed via authorized pharmaceutical wholesalers globally. In the United States, key distributors include:
- Cardinal Health
- McKesson Corporation
- AmerisourceBergen
Internationally, Alcon works with regional distributors aligned with regulatory requirements of each country.
Logistics
Distribution involves temperature-controlled supply chains to maintain drug stability. Logistics providers include specialized pharmaceutical logistics companies such as DHL Supply Chain and UPS Healthcare.
Regulatory and Quality Assurance
Suppliers must meet strict regulatory standards set by agencies such as the FDA, EMA, and other regional authorities. Quality assurance involves regular audits, stability testing, and compliance with GMP.
Summary of Supplier Roles
| Role |
Major Participants |
Notes |
| Active Pharmaceutical Ingredient (API) |
Zhenhua Pharmaceutical, North China Pharmaceutical |
Proprietary supply chain; limited information on exclusivity |
| Manufacturing (Finished Product) |
Alcon (Novartis) |
Sole manufacturer, global distribution hubs |
| Packaging and Logistics |
Various CMOs and Logistics Firms |
Tiered, region-specific partners |
| Distribution |
Alcoholic Wholesale Distributors |
Authorized by Alcon for regional markets |
Key Takeaways
- VIGAMOX is manufactured exclusively by Alcon, a Novartis division.
- API sources, primarily from Chinese manufacturers, supply moxifloxacin hydrochloride under GMP standards.
- Distribution channels are dominated by major pharmaceutical wholesalers with strict logistics protocols.
- Strategic and regulatory considerations limit transparency regarding some suppliers, especially for API production.
- The global supply chain involves multiple tiers but remains highly controlled due to the pharmaceutical nature.
FAQs
1. Who supplies the API for VIGAMOX?
Major API suppliers include Chinese firms such as Zhenhua Pharmaceutical and North China Pharmaceutical; specific contractual details are proprietary.
2. Does Alcon outsource any part of VIGAMOX production?
Yes, certain packaging and logistics activities are outsourced to specialized CMOs, but the API and final formulation manufacturing are conducted in Alcon’s facilities.
3. Are there alternative suppliers for VIGAMOX?
Currently, Alcon is the sole manufacturer; however, other companies produce moxifloxacin APIs for generic formulations outside VIGAMOX, but not for Alcon’s branded product.
4. How is supply chain security maintained?
Through GMP compliance, strict regulatory oversight, and tiered distribution agreements with authorized wholesalers.
5. Has supply chain disruption been reported for VIGAMOX?
There have been occasional shortages related to raw material availability and global logistics issues, but no sustained supply disruptions reported as of early 2023.
References
[1] Alcon. (2022). VIGAMOX product information. Retrieved from https://www.alcon.com
[2] European Medicines Agency. (2021). Moxifloxacin hydrochloride summary.
[3] Chinese pharmaceutical market reports. (2022). API supplier landscape.
